Network meta-analysis demonstrates the safety of pharmacotherapy for smoking cessation in cardiovascular patients

  title={Network meta-analysis demonstrates the safety of pharmacotherapy for smoking cessation in cardiovascular patients},
  author={Andrew L. Pipe},
  journal={Evidence-Based Medicine},
  pages={193 - 193}
  • A. Pipe
  • Published 4 June 2014
  • Medicine
  • Evidence-Based Medicine
Commentary on : Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014;129:28–41.[OpenUrl][1][Abstract/FREE Full Text][2] The importance of smoking cessation in the prevention and management of cardiovascular disease cannot be overestimated. Exposure to tobacco products, beginning in utero, causes substantial damage to vascular health, imposing dramatic public and personal health burdens over a… 
1 Citations

Pharmacotherapy for Smoking Cessation in Cardiovascular Patients

In general, all drugs seemed to be effective for smoking cessation and there was no clear evidence that these medications increase major cardiovascular side effects for patients with cardiovascular disease.



Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis

Smoking cessation therapies do not appear to raise the risk of serious cardiovascular disease events, and the use of cessation medications is recommended to increase the likelihood of quitting.

Managing tobacco use: the neglected cardiovascular disease risk factor.

An evidence-based approach for physicians is to routinely ask all patients about smoking status and SHS exposure, advise all smokers to quit and all patients to adopt smoke-free policies for their home and car, and offer all smokers in the office or hospital brief counselling, smoking cessation pharmacotherapy, and referral to local programmes where psychosocial support can be sustained in person or by telephone.

Smoking cessation: primacy in cardiovascular disease prevention.

  • A. Pipe
  • Medicine, Political Science
    Current opinion in cardiology
  • 2008
Irrespective of this, it is increasingly clear that the provision of ‘best-practice’ smoking cessation approaches should be seen as part of a fundamental standard of care provided to nicotine-addicted patients in all cardiac settings.

Smoking cessation for hospitalized smokers: an evaluation of the "Ottawa Model".

  • R. ReidK. Mullen A. Pipe
  • Medicine, Political Science
    Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
  • 2010
The Ottawa Model for Smoking Cessation was successfully implemented in 9 hospitals leading to significantly higher long-term cessation rates and was more likely to accomplish counseling for smokers than delivery of medications or postdischarge follow-up.

Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.

  • N. Benowitz
  • Biology, Medicine
    Annual review of pharmacology and toxicology
  • 2009
Genetic studies indicate roles for nicotinic receptor subtypes, as well as genes involved in neuroplasticity and learning, in development of dependence, and Pharmacotherapeutic approaches to tobacco addiction include nicotine replacement, bupropion, and varenicline.

New evidence that cigarette smoking remains the most important health hazard.

  • S. Schroeder
  • Medicine, Political Science
    The New England journal of medicine
  • 2013
Both articles review mortality trends over time for men and women according to smoking status, and both confirm that smoking remains a huge threat to the public's health.

Global effects of smoking, of quitting, and of taxing tobacco.

The magnitude of the disease burden from cigarette smoking worldwide and strategies to limit smoking are reviewed.